Clinical AML Registry and Biomaterial Database of the Study Alliance Leukemia (SAL)
Technische Universität Dresden
15,000 participants
Sep 1, 2010
OBSERVATIONAL
Conditions
Summary
This is a registry study in adult patients with newly diagnosed or refractory/relapsed acute myeloid leukemia. Investigator's sites: 51 sites in Germany. Primary objectives: * Identification of epidemiological data on AML: age, prognostic factors and subgroup distributions. Incidence and age distribution are compared with the data of population-related tumor registry. * Evaluation of the most important patient-relevant clinical endpoints (outcomes): relapse-free survival (RFS) / time to relapse (TTR), calculation of cumulative incidence of relapse (CIR) and overall survival (OS) * Documentation of treatment strategy
Eligibility
Inclusion Criteria3
- AML according to the WHO (World Health Organization) diagnostic criteria, including acute promyelocytic leukemia
- Age ≥ 18 years. There is no upper age limit.
- Signed written informed consent
Locations(51)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03188874